Stratec SE (SBS.DE), a German maker of analyzer and automation systems for In-Vitro-Diagnostic, reported that preliminary consolidated sales for the first nine months of 2024 declined to 176.3 million euros from 187.7 million euros last year.
The adjusted EBIT margin for the first nine months of 2024 will amount to 8.4% and thus almost match the previous year's level.
In addition, Stratec is shortly due to sign further additional orders with customers, most of which were not included in the original financial guidance for 2024. As a result, sales and earnings are expected to improve significantly in the fourth quarter of 2024 compared with the first nine months of 2024. The company accordingly expects to be able to make up for most of the shortfall in sales by the end of the year.
Given the ongoing volatility in the market climate, Stratec has decided to slightly adjust its sales guidance for 2024. The company now anticipates that its constant-currency sales will either remain stable or decline slightly compared to the previous year, a change from its earlier expectation of stable or slight growth in constant-currency sales.
By contrast, the 2024 guidance for the adjusted EBIT margin has been confirmed at around 10.0% to 12.0%.
Stratec said it will publish its final figures and its Quarterly Statement for the first nine months of 2024 on October 25, 2024.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.